524470 Stock Overview
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 524470 from our risk checks.
Syncom Formulations (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹13.78 |
| 52 Week High | ₹18.65 |
| 52 Week Low | ₹6.04 |
| Beta | 1.27 |
| 1 Month Change | 19.00% |
| 3 Month Change | -9.58% |
| 1 Year Change | 123.34% |
| 3 Year Change | 146.07% |
| 5 Year Change | 1,264.36% |
| Change since IPO | 816.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524470 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 8.6% | -0.1% | 1.8% |
| 1Y | 123.3% | 55.9% | 46.4% |
Return vs Industry: 524470 exceeded the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: 524470 exceeded the Indian Market which returned 46.4% over the past year.
Price Volatility
| 524470 volatility | |
|---|---|
| 524470 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524470 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524470's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 555 | Vijay Bankda | www.syncomformulations.com |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations.
Syncom Formulations (India) Limited Fundamentals Summary
| 524470 fundamental statistics | |
|---|---|
| Market cap | ₹12.95b |
| Earnings (TTM) | ₹263.83m |
| Revenue (TTM) | ₹2.50b |
49.1x
P/E Ratio5.2x
P/S RatioIs 524470 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524470 income statement (TTM) | |
|---|---|
| Revenue | ₹2.50b |
| Cost of Revenue | ₹1.52b |
| Gross Profit | ₹975.02m |
| Other Expenses | ₹711.19m |
| Earnings | ₹263.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 39.03% |
| Net Profit Margin | 10.56% |
| Debt/Equity Ratio | 29.6% |
How did 524470 perform over the long term?
See historical performance and comparison